Tassos joined Arix Bioscience as a Managing Director in June 2023. Prior to Arix, Tassos was an investment manager at IP Group, where he led several new investments and served on the board of privately held biotech companies including Oxular, Kynos Therapeutics and Storm Therapeutics.

He previously worked as an analyst at SR One, and has also held business development roles both in the UK and the US focusing on licensing and new company creation.

Tassos earned a PhD in Molecular Oncology at the University of Oxford and was a postdoctoral scholar at the University of Chicago.